Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.56 |
| ▸ | CCND1 | P24385 | 16/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 7/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.47 |
| ▸ | CDK9 | P50750 | 6/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002277 | 0.89 | CCNE1 (0.56) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL19868160 | 0.81 | CDK2 (0.60) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL19868152 | 0.79 | CCNE1 (0.56) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL5049489 | 0.77 | CDK2 (0.49) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL5412716 | 0.75 | ROCK2 (0.62) | — | |
| SCHEMBL22901104 | 0.74 | CDK2 (0.50) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL14391661 | 0.73 | MAPK8 (0.57) | CDK2 | |
| SCHEMBL19863598 | 0.72 | CCNE1 (1.00) | CDK2CCNE1CCND1CDK6CDK4 | |
| SCHEMBL19868282 | 0.72 | CDK2 (0.54) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL5031712 | 0.72 | CDK2 (0.56) | CDK2CCNE1CCND1CDK6CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1758871-B1 | PYRAZOLO PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | DING QINGJIE | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | CDK1, CDK4, CDK2 | CDK2 3/4885CCNE1 21/4885CCND1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.